Lowest-Rated StocksLowest-RatedNYSE:NVRO Nevro (NVRO) Stock Forecast, Price & News $28.27 +0.84 (+3.06%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$27.20▼$28.4250-Day Range$26.04▼$39.3252-Week Range$25.82▼$53.34Volume439,169 shsAverage Volume441,676 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$41.09 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nevro MarketRank™ ForecastAnalyst RatingHold2.08 Rating ScoreUpside/Downside45.4% Upside$41.09 Price TargetShort InterestHealthy4.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.45) to ($1.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector435th out of 983 stocksSurgical & Medical Instruments Industry44th out of 98 stocks 3.0 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 3 buy ratings, 7 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.09, Nevro has a forecasted upside of 45.4% from its current price of $28.27.Amount of Analyst CoverageNevro has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.17% of the float of Nevro has been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nevro has recently decreased by 6.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVRO. Previous Next 1.9 News and Social Media Coverage News SentimentNevro has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Nevro this week, compared to 3 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Nevro is held by insiders.Percentage Held by Institutions96.03% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to grow in the coming year, from ($2.45) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -2,827.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -2,827.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nevro (NYSE:NVRO) StockNevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.Read More Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address NVRO Stock News HeadlinesJune 2, 2023 | americanbankingnews.comNevro (NYSE:NVRO) Shares Gap Up to $26.04June 2, 2023 | americanbankingnews.comRoyal Bank of Canada Initiates Coverage on Nevro (NYSE:NVRO)June 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 31, 2023 | msn.comMorgan Stanley Maintains Nevro (NVRO) Equal-Weight RecommendationMay 31, 2023 | msn.comRBC Capital Initiates Coverage of Nevro (NVRO) with Outperform RecommendationMay 31, 2023 | msn.comRBC Capital starts Nevro at outperform, views stock as undervaluedMay 28, 2023 | americanbankingnews.comNevro Corp. (NYSE:NVRO) Receives $46.09 Consensus Price Target from BrokeragesMay 22, 2023 | finance.yahoo.comNevro to Present at Jefferies Healthcare ConferenceJune 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 21, 2023 | americanbankingnews.comTruist Financial Cuts Nevro (NYSE:NVRO) Price Target to $32.00May 18, 2023 | finance.yahoo.comNevro Corp.'s (NYSE:NVRO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatioMay 18, 2023 | americanbankingnews.comNevro (NYSE:NVRO) Now Covered by Analysts at StockNews.comMay 15, 2023 | msn.comOppenheimer Upgrades Nevro (NVRO)May 15, 2023 | msn.comNevro gains as Oppenheimer upgrades citing balanced risk rewardMay 15, 2023 | americanbankingnews.comOppenheimer Upgrades Nevro (NYSE:NVRO) to "Outperform"May 10, 2023 | msn.comNevro: Potentially Better Than Traditional SCS Treatment For Pain And UndervaluedMay 10, 2023 | americanbankingnews.comNevro (NYSE:NVRO) Hits New 12-Month Low at $26.43May 3, 2023 | americanbankingnews.comWilliam Blair Analysts Lower Earnings Estimates for Nevro Corp. (NYSE:NVRO)May 2, 2023 | americanbankingnews.comBrokers Set Expectations for Nevro Corp.'s Q2 2023 Earnings (NYSE:NVRO)May 2, 2023 | americanbankingnews.comNevro Corp. Forecasted to Earn Q2 2023 Earnings of ($0.65) Per Share (NYSE:NVRO)May 1, 2023 | americanbankingnews.comNevro Corp. (NYSE:NVRO) Receives $47.50 Average Price Target from BrokeragesApril 30, 2023 | americanbankingnews.comNevro (NYSE:NVRO) Price Target Cut to $34.00 by Analysts at Piper SandlerApril 29, 2023 | americanbankingnews.comNevro (NYSE:NVRO) Shares Gap Down After Analyst DowngradeApril 27, 2023 | finance.yahoo.comNevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company ManualApril 26, 2023 | seekingalpha.comNevro Corp. 2023 Q1 - Results - Earnings Call PresentationApril 26, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for Nevro Corp. (NYSE:NVRO) Issued By OppenheimerApril 25, 2023 | americanbankingnews.comBrokers Issue Forecasts for Nevro Corp.'s Q1 2024 Earnings (NYSE:NVRO)See More Headlines NVRO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVRO Company Calendar Last Earnings4/26/2023Today6/03/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVRO CUSIPN/A CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,087Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.09 High Stock Price Forecast$72.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+45.4%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3 million Net Margins0.55% Pretax Margin0.89% Return on Equity-34.61% Return on Assets-17.71% Debt Debt-to-Equity Ratio0.62 Current Ratio7.15 Quick Ratio5.63 Sales & Book Value Annual Sales$406.36 million Price / Sales2.49 Cash FlowN/A Price / Cash FlowN/A Book Value$8.41 per share Price / Book3.36Miscellaneous Outstanding Shares35,820,000Free Float34,742,000Market Cap$1.01 billion OptionableOptionable Beta0.88 Key ExecutivesD. Keith GrossmanChairman, President & Chief Executive OfficerBryan HixVice President-Commercial OperationsRoderick H. MacLeodChief Financial Officer & Senior Vice PresidentDavid CarawayChief Medical Officer & Senior Vice PresidentChristopher ChristoforouSenior Vice President-Technical OperationsKey CompetitorsAtrionNASDAQ:ATRIOrthoPediatricsNASDAQ:KIDSSI-BONENASDAQ:SIBNLongview Acquisition Corp. IINYSE:LGVCardiovascular SystemsNASDAQ:CSIIView All CompetitorsInstitutional OwnershipNew York State Common Retirement FundSold 6,591 shares on 5/18/2023Ownership: 0.051%Fred Alger Management LLCSold 9,757 shares on 5/16/2023Ownership: 3.278%Jane Street Group LLCBought 11,600 shares on 5/16/2023Ownership: 0.000%Graham Capital Management L.P.Bought 12,364 shares on 5/16/2023Ownership: 0.137%Susquehanna International Group LLPBought 18,400 shares on 5/16/2023Ownership: 0.000%View All Institutional Transactions NVRO Stock - Frequently Asked Questions Should I buy or sell Nevro stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares. View NVRO analyst ratings or view top-rated stocks. What is Nevro's stock price forecast for 2023? 12 Wall Street analysts have issued 1 year target prices for Nevro's shares. Their NVRO share price forecasts range from $31.00 to $72.00. On average, they predict the company's share price to reach $41.09 in the next year. This suggests a possible upside of 45.4% from the stock's current price. View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts. How have NVRO shares performed in 2023? Nevro's stock was trading at $39.60 at the beginning of 2023. Since then, NVRO shares have decreased by 28.6% and is now trading at $28.27. View the best growth stocks for 2023 here. When is Nevro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our NVRO earnings forecast. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) announced its quarterly earnings results on Wednesday, April, 26th. The medical equipment provider reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. The medical equipment provider had revenue of $96.33 million for the quarter, compared to analyst estimates of $95.35 million. Nevro had a net margin of 0.55% and a negative trailing twelve-month return on equity of 34.61%. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.98) earnings per share. What ETFs hold Nevro's stock? ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI), What guidance has Nevro issued on next quarter's earnings? Nevro updated its second quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $110.00 million-$112.00 million, compared to the consensus revenue estimate of $111.52 million. What is D. Keith Grossman's approval rating as Nevro's CEO? 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG). What is Nevro's stock symbol? Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO." Who are Nevro's major shareholders? Nevro's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.88%), ArrowMark Colorado Holdings LLC (3.72%), Fred Alger Management LLC (3.28%), State Street Corp (2.58%), Geode Capital Management LLC (1.84%) and Principal Financial Group Inc. (1.81%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nevro's stock price today? One share of NVRO stock can currently be purchased for approximately $28.27. How much money does Nevro make? Nevro (NYSE:NVRO) has a market capitalization of $1.01 billion and generates $406.36 million in revenue each year. The medical equipment provider earns $3 million in net income (profit) each year or ($0.01) on an earnings per share basis. How many employees does Nevro have? The company employs 1,087 workers across the globe. How can I contact Nevro? Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com. This page (NYSE:NVRO) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.